In particular, pharmacological inhibitors targeting the ErbB2 RTK family (EGFR, ErbB2, ErbB3, and ErbB4) are standard of care for subsets of breast cancer and NSCLC patients and have been shown to elicit potent anti-tumor immune responses in the tumor microenvironment, thereby increasing the clinical impact of immune checkpoint inhibitors (Supplementary Table S1 and as reviewed in [88]). Here, ERBB2 is linked to neoplasm.